Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
By Lori Solomon HealthDay Reporter
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a study published online May 11 in eClinicalMedicine.
Yael Wolff Sagy, Ph.D., from Clalit Health Services in Tel-Aviv, Israel, and colleagues conducted an observational, retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation GLP-1 RA or with bariatric metabolic surgery (BMS). Analysis included 3,178 matched pairs.
The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted hazard ratio for GLP-1 RA versus BMS, 1.11; 95 percent confidence interval, 0.86 to 1.44). Assessment of mediation through weight loss had an estimated direct effect of 41 percent relative risk reduction of the pharmacotherapy.
"The estimated direct effect of GLP-1 RA versus BMS on the risk for ORC may point at additional pathways beyond weight loss in which GLP-1 RAs contribute to the decreased risk for ORC, such as reducing inflammation," the authors write. "However, future studies are needed to validate the observed effects and explore the underlying mechanisms."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
AAP Updates Guidelines for Pediatric Atopic Dermatitis Management
MONDAY, May 19, 2025 -- In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for the treatment of children...
MRI-Guided Biopsy Linked to Durability of Active Surveillance in Prostate Cancer
MONDAY, May 19, 2025 -- Use of magnetic resonance imaging (MRI)-guided biopsy (MRGB) could increase the durability of active surveillance (AS) in men with prostate cancer...
Wearable Sensor Can Monitor Sleep Apnea Treatment Response
MONDAY, May 19, 2025 -- A wearable pulse oximeter and connected software platform (Apnimed) shows promise for monitoring obstructive sleep apnea (OSA) and other sleep-related...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.